caa a22 4500 605520488 CHVBK 20210128100735.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s00223-015-0040-3 doi (NATIONALLICENCE)springer-10.1007/s00223-015-0040-3 Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study [Elektronische Daten] [C. Carbonell-Abella, A. Pages-Castella, M. Javaid, X. Nogues, A. Farmer, C. Cooper, A. Diez-Perez, D. Prieto-Alhambra] Although a number of reports suggest very low persistence with oral bisphosphonates, there is limited data on persistence with other anti-osteoporosis medications. We compare rates of early discontinuation (in the first year) with all available outpatient anti-osteoporosis drugs in Catalonia, Spain. We conducted a population-based retrospective cohort study using data from the SIDIAP database. SIDIAP contains computerized primary care records and pharmacy dispensing data for >80% of the population of Catalonia (>5 million people). All SIDIAP participants starting an anti-osteoporosis drug between 1/1/2007 and 30/06/2011 (with 2years wash-out) were included. We modelled persistence as the time between first prescription and therapy discontinuation (refill gap of at least 6months) using Fine and Gray survival models with competing risk for death. We identified 127,722 patients who started any anti-osteoporosis drug in the study period. The most commonly prescribed drug was weekly alendronate (N=55,399). 1-Year persistence ranges from 40% with monthly risedronate to 7.7% with daily risedronate, and discontinuation was very common [from 49.5% (monthly risedronate) to 84.4% (daily risedronate)] as was also switching in the first year of therapy [from 2.8% (weekly alendronate) to 10% (daily alendronate)]. Multivariable-adjusted models showed that only monthly risedronate had better one-year persistence than weekly alendronate and teriparatide equivalent, whilst all other therapies had worse persistence. Early discontinuation with available anti-osteoporosis oral drugs is very common. Monthly risedronate, weekly alendronate, and daily teriparatide are the drugs with the best persistence, whilst daily oral drugs have 40-60% higher first-year discontinuation rates compared to weekly alendronate. Springer Science+Business Media New York, 2015 Electronic health records nationallicence Epidemiology nationallicence Medication adherence nationallicence Osteoporosis nationallicence Catalonia nationallicence Primary health care nationallicence Carbonell-Abella C. GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain aut Pages-Castella A. GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain aut Javaid M. Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK aut Nogues X. Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain aut Farmer A. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK aut Cooper C. Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK aut Diez-Perez A. Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain aut Prieto-Alhambra D. GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain aut Calcified Tissue International Springer US; http://www.springer-ny.com 97/6(2015-12-01), 535-541 0171-967X 97:6<535 2015 97 223 https://doi.org/10.1007/s00223-015-0040-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00223-015-0040-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Carbonell-Abella C. GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain aut NATIONALLICENCE 700 1- Pages-Castella A. GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain aut NATIONALLICENCE 700 1- Javaid M. Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK aut NATIONALLICENCE 700 1- Nogues X. Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain aut NATIONALLICENCE 700 1- Farmer A. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK aut NATIONALLICENCE 700 1- Cooper C. Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK aut NATIONALLICENCE 700 1- Diez-Perez A. Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain aut NATIONALLICENCE 700 1- Prieto-Alhambra D. GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain aut NATIONALLICENCE 773 0- Calcified Tissue International Springer US; http://www.springer-ny.com 97/6(2015-12-01), 535-541 0171-967X 97:6<535 2015 97 223